MARKET

ATRC

ATRC

AtriCure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.71
+0.91
+1.20%
After Hours: 76.71 0 0.00% 16:19 09/17 EDT
OPEN
76.67
PREV CLOSE
75.80
HIGH
77.37
LOW
75.40
VOLUME
676.34K
TURNOVER
--
52 WEEK HIGH
85.50
52 WEEK LOW
34.04
MARKET CAP
3.52B
P/E (TTM)
-59.3271
1D
5D
1M
3M
1Y
5Y
Insider Sell: Atricure
MT Newswires · 1d ago
Atricure Inc (ATRC) COO Douglas J Seith Sold $1.6 million of Shares
GuruFocus News · 3d ago
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19th Annual Global He...
Business Wire · 08/31 12:00
Return on Capital Employed Insights for AtriCure
After pulling data from Benzinga Pro it seems like during Q2, AtriCure's (NASDAQ:ATRC) reported sales totaled $71.38 million. Despite a 5.09% in earnings, the company posted a loss of $15.08 million.
Benzinga · 08/20 17:55
Insider Trends: Insider Adds to Selling Trend at AtriCure
MT Newswires · 08/17 08:35
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Simply Wall St. · 08/12 06:11
Atricure Inc (ATRC) COO Douglas J Seith Sold $570,781 of Shares
GuruFocus News · 08/12 04:15
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)
Benzinga · 08/06 11:42
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRC. Analyze the recent business situations of AtriCure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRC stock price target is 96.71 with a high estimate of 120.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 282
Institutional Holdings: 48.87M
% Owned: 106.52%
Shares Outstanding: 45.88M
TypeInstitutionsShares
Increased
64
2.93M
New
41
802.63K
Decreased
79
3.72M
Sold Out
21
293.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
B. Kristine Johnson
President/Chief Executive Officer/Director
Michael Carrel
Chief Financial Officer
Angela Wirick
Chief Operating Officer
Douglas Seith
Chief Technology Officer
Salvatore Privitera
Chief Marketing Officer
Justin Noznesky
Director
Deborah Telman
Director
Maggie Yuen
Independent Director
Mark Collar
Independent Director
Daniel Florin
Independent Director
Regina Groves
Independent Director
Karen Prange
Independent Director
Sven Wehrwein
Independent Director
Robert White
No Data
  • All
  • Financials
  • Insiders
More
About ATRC
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Webull offers kinds of AtriCure Inc. stock information, including NASDAQ:ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.